Full-Time

IMUAM Deployment Manager

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Hyderabad, Telangana, India + 1 more

More locations: Bengaluru, Karnataka, India

Hybrid

Hybrid work arrangement; multiple offices in India.

Bachelor's

Category
IT & Security (2)
,
Required Skills
SAP Products
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Bachelor’s degree or university-level qualification in a relevant field, such as Finance, Supply Chain, IT, or Engineering.
  • Minimum of 8 years’ relevant experience in international companies, including at least 5 years of people management or team leadership experience.
  • Expertise in business role design and SAP security concepts.
  • Demonstrable experience managing ERP deployment programs and project delivery in sophisticated, multi-functional environments.
  • Solid understanding of sophisticated system landscapes and global template design.
  • Good knowledge of SAP S/4HANA authorization concepts and familiarity with compliance requirements such as SOX, GxP, IT, and Privacy.
  • Experience in SAP S/4HANA implementation projects.
  • Specialist knowledge of SAP GRC Access Control, Process Control, and identity management tools.
  • Good understanding of SoD, mitigation, and remediation concepts.
  • Good knowledge of risk matrix and rule set maintenance.
  • Specialist knowledge of data analysis, data conversion, and migration.
  • Solid project management, planning, prioritization, and execution leadership skills.
  • Ability to lead and empower teams in a virtual or remote working environment.
  • Strong collaborator management, communication, collaboration, presentation, and conflict resolution skills.
  • Strong analytical, decision-making, and problem-solving skills.
  • Excellent oral and written English skills.
  • Experience influencing and collaborating across large business, IT, security, and compliance organizations.
  • Collaborative, value-based, and outcome-oriented leadership style with the ability to manage teams, develop talent, and drive accountability.
  • Experience establishing or operating UAM governance frameworks, including standards, policies, decision forums, and performance metrics to supervise progress and accountability.
  • Experience managing compliance requirements, change impacts, and stakeholder expectations during technology or process transformation programs.
Responsibilities
  • Manage UAM deployment delivery for individual Transcend SAP S/4HANA releases in a regulated pharmaceutical environment, ensuring execution of the global UAM deployment strategy in line with deployment milestones, quality expectations, and program governance requirements.
  • Lead, coach, and develop a team of approximately 3-5 Security Analysts, setting priorities, providing guidance, supporting performance and development discussions, and aligning team activities with J&J and UAM talent development expectations.
  • Own UAM deployment readiness across all deployment phases, ensuring persona design, testing, cutover/provisioning, and hypercare activities are planned, resourced, monitored, and completed in line with release milestones and entry/exit criteria.
  • Drive planning, prioritization, and execution control across UAM deployment activities, including progress tracking, dependency management, risk and issue escalation, and integration with broader program plans.
  • Oversee role design quality and compliance health checks before build, before cutover, and after go-live to confirm alignment with authorization principles, SoD controls, and applicable compliance expectations.
  • Manage cutover planning for access deployment activities, including role transport sequencing, user provisioning readiness, emergency access planning, business validation steps, issue escalation, and stakeholder alignment.
  • Manage hypercare support and transition to steady state, ensuring access issues are prioritized, root causes are understood, remediation actions are tracked, and ownership is clearly handed over to operational teams.
  • Provide oversight of SoD risks, sensitive access, and mitigation actions during deployment, ensuring risks are visible, appropriately escalated, and managed to support compliant access enablement in regulated environments.
  • Establish, monitor, and communicate UAM deployment KPIs and management reporting, including defect volumes, role readiness, cutover completion, provisioning accuracy, open risks, and hypercare stabilization trends.
  • Drive continuous improvement of the UAM deployment framework by applying lessons learned from releases to strengthen methodology, controls, templates, deployment efficiency, taxonomy, governance, and the operating model.
Desired Qualifications
  • Agility Jumps
  • Business Continuity Management (BCM)
  • Compliance Frameworks
  • Compliance Management
  • Financial Analysis
  • Financial Risk Management (FRM)
  • Internal Controls
  • Mentorship
  • Process Improvements
  • Regulatory Environment
  • Risk Assessments
  • Risk Measurement
  • Stakeholder Engagement
  • Systems Thinking
  • Tactical Planning
  • Technical Credibility

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.